InvestorsHub Logo
Followers 481
Posts 60472
Boards Moderated 18
Alias Born 09/20/2001

Re: Rymankoly post# 78

Monday, 12/05/2016 3:24:55 PM

Monday, December 05, 2016 3:24:55 PM

Post# of 21531

Data presented in the first poster highlights the evaluation of a maximum tolerated dose (MTD) of ANAVEX 2-73 as primary endpoint of the Phase 2a study in mild-to-moderate Alzheimer’s patients, as well as additional clinical safety data and positive unexpected therapeutic response events, such as improved mood, improved social engagement and increased independent activities through 31 weeks. The second poster will present efficacy data through 31 weeks.



https://globenewswire.com/news-release/2016/07/24/858378/0/en/Anavex-Presents-31-Week-Safety-Data-from-Phase-2a-Study-of-ANAVEX-2-73-in-Alzheimer-s-Patients-at-AAIC-2016.html



In Peace, In War

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNPX News